CHEK vs. AVTX, NNVC, TNXP, BTCY, SNTI, NXGL, MIRA, TRAW, AIH, and RDHL
Should you be buying Check-Cap stock or one of its competitors? The main competitors of Check-Cap include Avalo Therapeutics (AVTX), NanoViricides (NNVC), Tonix Pharmaceuticals (TNXP), Biotricity (BTCY), Senti Biosciences (SNTI), NEXGEL (NXGL), MIRA Pharmaceuticals (MIRA), Traws Pharma (TRAW), Aesthetic Medical International Holdings Group (AIH), and RedHill Biopharma (RDHL). These companies are all part of the "medical" sector.
Avalo Therapeutics (NASDAQ:AVTX) and Check-Cap (NASDAQ:CHEK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 0.2% of Avalo Therapeutics shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Check-Cap had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 2 mentions for Check-Cap and 1 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.50 beat Check-Cap's score of -1.00 indicating that Check-Cap is being referred to more favorably in the news media.
Check-Cap has lower revenue, but higher earnings than Avalo Therapeutics. Check-Cap is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.
Check-Cap has a net margin of 0.00% compared to Check-Cap's net margin of -1,639.50%. Avalo Therapeutics' return on equity of -47.85% beat Check-Cap's return on equity.
Avalo Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.
Check-Cap received 365 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 66.07% of users gave Check-Cap an outperform vote while only 31.25% of users gave Avalo Therapeutics an outperform vote.
Summary
Check-Cap beats Avalo Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Check-Cap News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHEK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHEK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Check-Cap Competitors List
Related Companies and Tools
